Biogen Idec, a world’s oldest independent biotechnology company, has created a new research consortium in collaboration with several leading academic research centres that will leverage a range of ...

Great biotech companies tend to dominate at least one indication. In Biogen's case, that indication is multiple sclerosis. Biogen's Avonex and Tysabri are long-standing blockbuster treatments for ...

Biogen Idec has partnered with Google X, Google's business unit for long-term “moonshot” projects, to study outside factors that might contribute to the progression of multiple sclerosis (MS), ...

Former Biogen Idec executive Mark Matthews has been appointed to a top sales and marketing post of drug development company Pozen as the company prepares for an expected late 2013 launch of its lead ...

S&P 500 component Biogen IDEC Inc reported net income above Wall Street’s expectations for the third quarter. Biogen Idec is a global biotechnology company that meets the rising needs of therapeutic ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Cambridge neighbors Biogen Idec Inc. and Alnylam ...

Ahead of the company's earnings announcement, analysts are expecting a positive EPS reading of $1.51/share and revenues of $1.27 billion. Biogen Idec's latest numbers will no doubt be compared with ...

This year has turned against biotech investors, as the long-awaited correction came on hard in March and April. While conditions seem to have stabilized for the time being, Biogen Idec remains an ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Biogen Idec drug Rituxan is the world's most prescribed ...

Idec Pharmaceuticals Corp. and Biogen Inc. announced yesterday that they would merge in a $6.8 billion deal that will create a powerhouse in the biotechnology industry, with the new company earning ...

BOSTON, June 10 (Reuters) - Biogen Idec Inc , one of the world's biggest biotechnology companies, said on Tuesday that two proxy advisory firms have recommended that shareholders vote in favor of its ...

BOSTON, Jan. 27 (Reuters) - Proxy materials have been delivered to Biogen Idec Inc by Carl Icahn, as the billionaire investor seeks greater control of the biotechnology company's board, according to a ...